Rachel Layman, MD
Current OSU Appointments
Education and Training
- Bachelor of Arts, Case Western Reserve University
- M.D., Case Western Reserve University
- Internal Medicine Residency, University Hospitals of Cleveland
- Hematology and Oncology Fellowship, University of Michigan
Dr. Layman joined the Division of Solid Tumor Oncology in 2008. Her research interests include investigational therapeutics and breast cancer prevention. She serves as the local principal investigator (PI) on several clinical trials evaluating new therapies for advanced breast cancer. For example, randomized phase II trials women with advanced breast cancer including capecitabine +/- vascular growth factor receptor inhibitor; and a trial for women with previously untreated triple negative breast cancers or HER2 overexpressing breast cancers with ganetespib, a heat shock protein 90 inhibitor, that inhibits several pathways critical to growth of these tumors. Dr. Layman also sees women at risk of developing breast cancer and is a member of the High Risk Clinic. The High Risk Clinic is dedicated to the identification of women and family members that virtue of the genes they were born with have a higher than average risk of developing breast and other cancers, and ways to prevent breast cancer. Dr. Layman provides clinical care to women with all stages of invasive breast cancer and women who are high risk of developing breast cancer.